Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL954043 | 0.86 | PIK3CD (0.59) | PIK3CDCYP1A2TDP1 | |
| SCHEMBL976669 | 0.82 | PIK3CD (0.47) | PIK3CDCYP1A2TDP1PTGS2PTGS1 | |
| SCHEMBL17718416 | 0.81 | PTGS2 (0.52) | PIK3CDTDP1IDO1PTGS2PTGS1 | |
| SCHEMBL12922271 | 0.77 | TDP1 (0.61) | PIK3CDCYP1A2TDP1HSD17B10POLB | |
| SCHEMBL11411270 | 0.76 | PKM (0.45) | PIK3CDCYP1A2TDP1IDO1PTGS2 | |
| SCHEMBL973303 | 0.76 | PIK3CG (0.56) | PIK3CDHSD17B10 | |
| SCHEMBL17718363 | 0.75 | PIK3CG (0.44) | PIK3CDHSD17B10POLB | |
| SCHEMBL975962 | 0.75 | PIK3CD (0.69) | PIK3CD | |
| SCHEMBL13150998 | 0.73 | CYP1A2 (0.41) | PIK3CDCYP1A2TDP1IDO1HSD17B10 | |
| SCHEMBL14639742 | 0.68 | DYRK1A (0.43) | CYP1A2TDP1HSD17B10MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11401280-B2 | Pyrimidinones as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2022-08-02 | — | — | US | disclosed |
| US-20210253601-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE HOLDINGS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20210253601-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE HOLDINGS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-10829502-B2 | Pyrimidinones as PI3K inhibitors | INCYTE CORPORATION (US) | 2020-11-10 | — | — | US | disclosed |
| US-10829502-B2 | Pyrimidinones as PI3K inhibitors | INCYTE CORPORATION (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200123176-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION | 2020-04-23 | — | — | US | disclosed |
| US-20200123176-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION | 2020-04-23 | — | — | US | disclosed |
| US-10428087-B2 | Pyrimidinones as PI3K inhibitors | INCYTE CORPORATION (US) | 2019-10-01 | — | — | US | disclosed |
| US-10428087-B2 | Pyrimidinones as PI3K inhibitors | INCYTE CORPORATION (US) | 2019-10-01 | — | — | US | disclosed |
| US-20180362546-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION | 2018-12-20 | — | — | US | disclosed |
| EP-2448938-B9 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORP (US) | 2015-06-10 | — | — | EP | disclosed |
| EP-2845856-A1 | Pyrimidinones as PI3K inhibitors | Incyte Corporation (US) | 2015-03-11 | — | — | EP | disclosed |
| US-8940752-B2 | Pyrimidinones as PI3K inhibitors | INCYTE CORPORATION (US) | 2015-01-27 | — | — | US | disclosed |
| US-8940752-B2 | Pyrimidinones as PI3K inhibitors | INCYTE CORPORATION (US) | 2015-01-27 | — | — | US | disclosed |
| US-8940752-B2 | Pyrimidinones as PI3K inhibitors | INCYTE CORPORATION (US) | 2015-01-27 | — | — | US | disclosed |
| EP-2448938-B1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORP (US) | 2014-05-28 | — | — | EP | disclosed |
| US-20140121222-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2014-05-01 | — | — | US | disclosed |
| US-20110015212-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-01-20 | — | — | US | disclosed |
| US-20110015212-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-01-20 | — | — | US | disclosed |
| US-20110015212-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11401280-B2 | Pyrimidinones as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885CYP1A2 2027/4885TDP1 767/4885 |
| US-10428087-B2 | Pyrimidinones as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885CYP1A2 2027/4885TDP1 767/4885 |
| US-20140121222-A1 | PYRIMIDINONES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885CYP1A2 2027/4885TDP1 767/4885 |
| US-20210253601-A1 | PYRIMIDINONES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885CYP1A2 2027/4885TDP1 767/4885 |
| US-10829502-B2 | Pyrimidinones as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885CYP1A2 2027/4885TDP1 767/4885 |
| US-20180362546-A1 | PYRIMIDINONES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885CYP1A2 2027/4885TDP1 767/4885 |
| US-20200123176-A1 | PYRIMIDINONES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885CYP1A2 2027/4885TDP1 767/4885 |
| US-20110015212-A1 | PYRIMIDINONES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885CYP1A2 2027/4885TDP1 767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.